|
 The drug, deucravacitinib, met the main goals in a late-stage study,
with more patients given a 6mg dose once a day achieving a 75%
improvement in psoriasis compared with a placebo, as measured by a
scale called the Psoriasis Area Severity Index, after 16 weeks of
treatment.
The company said the study also met a secondary goal of being more
effective than Otezla in a proportion of patients showing
improvement at week 16.
The results are from the second of two global late-stage studies
comparing the drug to a placebo and Otezla. Positive results from
the first of the two trials were reported in November 2020.
[to top of second column] |
 The company said it plans to
share detailed trial results at a future medical
meeting.
Psoriasis is a chronic, autoimmune inflammatory
disorder that results in sometimes painful,
scaly and inflamed skin patches, and is the most
prevalent autoimmune disease in the United
States, according to the National Institutes of
Health.
(Reporting by Vishwadha Chander in Bengaluru;
Editing by Krishna Chandra Eluri)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
